Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Aclarion, Inc. Common Stock

The first, evidence-supported, SaaS platform to leverage MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.

Tech Coast Angels

Aclarion

Chronic low back pain is a life-changing condition that prevents many individuals from living full and healthy lives. And finding the right treatment option for each patient’s unique situation can take months, if not years, to find. 
 
With Nociscan, patient-specific biomarker data helps physicians quickly assess which discs are potentially the source of a patient’s pain so physicians can optimize treatment strategies and help patients get back to an active, pain-free life.
 
Patients around the world are already experiencing the benefits of Nociscan. To learn more about how Nociscan can help you or a loved one, visit www.aclarion.com.
 
#ACON #ACONW #spine #nasdaq #lowbackpain

Last weekend at ISASS 2023, Leslie Wilson presented a cost-effectiveness abstract overviewing the initial findings of the EVAL study (Economic Value Analysis of Low back pain). The study found that Nociscan demonstrated statistical dominance over provocative discography with the potential to save the US healthcare system $283M to $441M annually. Read the full release here. https://lnkd.in/gMNt2uMw

#ACON #ACONW #nasdaq #lowbackpain #nociscan #spinesurgery #ISASS

New and compelling healthcare economics data from the EVAL Study (Economic Value Analysis of Low back pain Study) will be presented this week at ISASS 2023 in San Francisco! 

Join Aclarion on Saturday, June 3 in Salon 13-15 at 10:34 am to learn about the initial findings of this pivotal economic analysis of the Nociscan solution for the treatment of low back pain. 

Presentation title: Cost-effectiveness of novel, non-invasive diagnostic test for chronic low back pain. 
Presenter: Leslie Wilson, Professor at UCSF. 

#ACON #ACONW #ISASS23 #lowbackpain #spinesurgery #nasdaq

Aclarion announced today their commercial agreement with the prestigious London Clinic and London Spine Clinic. The London Clinic is one of the UK’s largest and most renowned independent hospitals. Based in the heart of London’s medical district, the Clinic has a heritage of investing in the latest technologies and providing exceptional medical care through state-of-the-art facilities.

“The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options available to them.  Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis,” said John Sutcliffe MD, Neurosurgeon, and Founder of London Spine Clinic.

Read the full announcement here. https://lnkd.in/gAmfkDQT

#ACON #ACONW #nasdaq #londonspineclinic #londonclinic #nociscan #spinesurgery

Aclarion’s CEO Brent Ness was recently interviewed by Proactive about the value of the Nociscan solution when treating patients with chronic low back pain and the corporate milestones that the company has recently achieved. Watch the full interview here. https://lnkd.in/gzEPAhkm

#ACON #ACONW #nasdaq #nociscan #lowbackpain #spine #spinesurgery

Wonderful Aclarion symposium today at SpineWeek in Melbourne. Standing room only to hear spine experts Sigurd Berven MD and Jeff Lotz PhD discuss the value of the Nociscan solution in addressing the question of Where’s the Pain? The clinical and economic data are clear: Nociscan improves clinical outcomes and has the potential to significantly reduce the cost of care. Visit www.aclarion.com to learn how you can bring Nociscan to your spine center. 

#ACON #ACONW #nasdaq #spineweek #painmanagement #pain #nociscan #spinesurgery

Attending SpineWeek in Melbourne next week? If so, join us Tuesday, May 2 for a sponsored symposium, Where’s The Pain?, led by renowned spine experts Sigurd Berven, MD and Jeff Lotz, PhD. New clinical and economic data will be presented demonstrating the value of the Nociscan solution to aid in the treatment of chronic low back pain. Hope to see you there.

#ACON #ACONW #nociscan #spineweek #spine #nasdaq #pain #painmanagement

We’re excited to announce the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan. Success rates at 2 years for DLBP low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs. (85% vs. 63%; p=0.07). Access the full article at https://lnkd.in/dCREgnkE

#ACON #ACONW #spinesurgery #nociscan #lowbackpain

Great debate last Friday at the 2023 Annual AANS/CNS Spine Summit between Juan Uribe, MD and Christopher Ames, MD on the role of AI and ML in spine surgery. Important topics raised by both sides and clearly, the future of spine care will be influenced by this growing field. 

Thank you, Dr. Uribe and Dr. Ames, for your continued commitment to advancing care for patients suffering from chronic low back pain.

#ACON #ACONW #spine #AI #machinelearning

Great topic for a debate! Looking forward to tomorrow's discussion.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	501.03K -	859.53K 71.55%	1.06M 23.27%	457.56K 56.82%	760.53K 66.22%
accumulated other comprehensive income loss
cash and cash equivalents	128.16K -	14.98K 88.31%	452.53K 2,920.09%	1.47M 225.46%	1.03M 29.99%
cash and short term investments	128.16K -	14.98K 88.31%	452.53K 2,920.09%	1.47M 225.46%	1.03M 29.99%
common stock	68 -	68 0%	68 0%	79 16.18%	8 89.87%
deferred revenue		3.14M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets	1.16M -	1.17M 0.48%	1.14M 2.09%	1.21M 6.09%	1.17M 3.77%
intangible assets	1.16M -	1.17M 0.48%	1.14M 2.09%	1.21M 6.09%	1.17M 3.77%
inventory				301.33K -
long term debt
long term investments
net debt	387.39K -	2.36M 509.69%	1.55M 34.48%	-1.47M 195.18%	94.66K 106.43%
net receivables	14.70K -	22.50K 53.13%	6.28K 72.09%	18.57K 195.68%	13.42K 27.71%
other assets				1 -	1 0%
other current assets	75.65K -	59.64K 21.16%	273.39K 358.38%	195.53K 28.48%	144.29K 26.21%
other current liabilities	2.12M -	2M 5.47%	4.56M 127.96%	960.65K 78.93%	1.30M 35.48%
other liabilities				-457.56K -
other non current assets					100.59K -
other non current liabilities				457.56K -
othertotal stockholders equity	18.74M -	18.85M 0.56%	26.16M 38.79%	41.69M 59.41%	43.55M 4.46%
preferred stock	186 -	186 0%	245 31.72%
property plant equipment net	48.51K -	25.62K 47.19%	12.64K 50.67%	3.35K 73.52%	1.78K 46.74%
retained earnings	-20.44M -	-25.93M 26.84%	-31.89M 22.97%	-39.91M 25.16%	-44.28M 10.96%
short term debt	515.55K -	2.38M 361.03%	2M 15.85%		1.13M -
short term investments
tax assets
tax payables
total assets	1.43M -	1.29M 9.69%	1.89M 46.27%	3.21M 69.68%	2.46M 23.27%
total current assets	218.51K -	97.13K 55.55%	732.20K 653.85%	1.99M 171.54%	1.19M 40.21%
total current liabilities	3.13M -	8.38M 167.38%	7.62M 9.03%	1.42M 81.39%	3.19M 124.77%
total debt	515.55K -	2.38M 361.03%	2M 15.85%		1.13M -
total investments
total liabilities	3.13M -	8.38M 167.38%	7.62M 9.03%	1.42M 81.39%	3.19M 124.77%
total liabilities and stockholders equity	1.43M -	1.29M 9.69%	1.89M 46.27%	3.21M 69.68%	2.46M 23.27%
total non current assets	1.21M -	1.19M 1.42%	1.16M 3.13%	1.22M 5.22%	1.27M 4.37%
total non current liabilities	-1 -	-2 100%		457.56K -
total stockholders equity	-1.70M -	-7.08M 316.21%	-5.73M 19.12%	1.79M 131.20%	-728.00K 140.72%

COM:ACLARION

Aclarion, Inc.

Last Close

0.18

22/11 21:00

Market Cap

1.44M

Beta: -

Volume Today

124.21K

Avg: -

Preview